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RNA viruses are a major threat to animals and plants. RNA interference (RNAi) and the 32 
interferon response provide innate antiviral defense against RNA viruses. Here we 33 
performed a large-scale screen using C. elegans and its natural pathogen, the Orsay virus 34 
(OrV), and identified cde-1 as important for antiviral defense. CDE-1 is a homologue of 35 
the mammalian TUT4/7 terminal uridylyltransferases; its catalytic activity is required for 36 
its antiviral function. CDE-1 uridylates the 3ʹ end of the OrV RNA genome and promotes its 37 
degradation, independently of the RNAi pathway. Likewise, TUT4/7 uridylate influenza A 38 
virus (IAV) mRNAs in mammalian cells. Deletion of TUT4/7 leads to increased IAV mRNA 39 
and protein levels. We have defined 3ʹ terminal uridylation of viral RNAs as a conserved 40 
antiviral defense mechanism. 41 
 42 
RNA viruses are a major threat to human health and food security. Understanding the fundamental 43 
mechanisms by which animals and plants combat viral infections might lead to new therapeutic 44 
antiviral approaches. RNA interference (RNAi) is an important antiviral pathway in most animals 45 
and plants: Dicer recognizes and cleaves the double-stranded viral RNA genome into virus-derived 46 
small interfering RNAs (viral siRNAs, viRNAs), which are loaded into Argonaute proteins to form 47 
the RNA-induced silencing complex (RISC) that in turn targets the viral RNA genome 1. 48 
Vertebrates have additionally evolved a cellular signaling-based pathway, the interferon response 49 
(IR): upon recognition of foreign RNAs (i.e. double-stranded or bearing a 5ʹ di/triphosphate), 50 
cytosolic receptors of the RIG-I family activate the IR which results in an antiviral state of the cell 51 
2,3. In the evolutionary arms race between viruses and their hosts, however, animals must have 52 
evolved a diverse range of antiviral strategies, to not solely rely on the RNAi or IR pathways.  53 
 54 
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Here, we develop a system for antiviral gene discovery using the nematode 55 
Caenorhabditis elegans (C. elegans) and identify 3ʹ terminal uridylation of viral RNAs as a third 56 
antiviral mechanism in animals. 57 
 58 
RESULTS 59 
A forward genetic screen identifies new genes required for antiviral defense in C. elegans 60 
We carried out a forward genetic screen to discover antiviral pathways in animals using C. elegans 61 
and its natural intestinal pathogen, the Orsay virus (OrV) 4-12. OrV is a bipartite positive-strand 62 
RNA virus related to the Nodaviridae 4. As is typical for positive sense RNA viruses, the genomic 63 
strand of the OrV is a template for translation. The OrV spreads horizontally in populations of C. 64 
elegans: it is taken up orally, infects only intestinal cells and probably exits through defecation 4. 65 
While C. elegans lacks an interferon pathway, a RIG-I ortholog, DRH-1, acts in viral recognition. 66 
DRH-1 forms a Viral Recognition Complex (ViRC) with the C. elegans Dicer (DCR-1) and the 67 
RNA-binding protein RDE-4 to link viral recognition to a dedicated antiviral RNAi pathway, 68 
involving the Argonaute protein RDE-1 5,11,13,14. DRH-1 also induces a transcriptional immune 69 
response through a STAT-dependent signaling pathway (e.g. the gene sdz-6, as shown by qRT-70 
PCR in Extended Data Fig. 1a) 10,15,16. However, the antiviral function of the DRH-1-mediated 71 
stress response remains to be elucidated. C. elegans also elicits a “biotic stress response” upon 72 
OrV infection that is independent of DRH-1 and partially overlaps with transcriptional responses 73 
induced by other types of pathogens, possibly as a result of perturbations in cell homeostasis and/or 74 
mechanical integrity (e.g. the gene lys-3, encoding an antibacterial enzyme, as shown by qRT-PCR 75 
in Extended Data Fig. 1a) 10. We generated a viral stress sensor transgene by placing the green 76 
fluorescent protein (GFP) under the control of the lys-3 promoter (allele mjIs228; Fig. 1a). Upon 77 
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infection, the level of GFP expression in the intestine mirrored the viral load in wild type, drh-1 78 
and rde-1 mutants (Extended Data Fig. 1b, c). We used chemical mutagenesis to screen ~50,000 79 
haploid genomes (Fig. 1b) and identified 16 isolates we named Ovid (Orsay Virus Immune 80 
Deficient; Fig. 1c and Supplementary Table 1). 13 out of 16 ovid mutants showed increased viral 81 
loads (Fig. 1c). ovid-3,4,5,10,12 are compromised in somatic RNAi, as tested by RNAi knockdown 82 
of the gene unc-22, which normally results in impaired locomation (Fig. 1c), and ovid-3,4,10 carry 83 
new alleles of RNAi genes mut-16, rde-4 and rrf-1, respectively (Table 1). To further stratify our 84 
Ovid isolates, we assayed DRH-1 pathway activation using the expression of the downstream 85 
induced gene sdz-6 as readout (Fig. 1d). Only ovid-1 phenocopied drh-1 mutants and we 86 
subsequently demonstrated that ovid-1 defines a new allele of drh-1 (Fig. 1d). We identified a 87 
number of additional candidate genes (Table 1). ovid-9 and ovid-11 mutants are neither defective 88 
in canonical RNAi nor in the DRH-1 pathway and thus represent candidate genes for novel 89 
antiviral defense mechanisms. 90 
 91 
The terminal uridylyltransferase CDE-1 is required for antiviral defense in C. elegans 92 
Whole-genome re-sequencing and genetic complementation tests revealed the causative mutation 93 
in ovid-9 to be a single-nucleotide nonsense mutation in the cde-1 gene (mj414, glutamine 910 to 94 
STOP) (Fig. 2a and Extended Data Fig. 2). cde-1 encodes a catalytically active 3ʹ-terminal RNA 95 
uridylyltransferase (TUT), which is a homologue of mammalian TUT4 and TUT7 enzymes 15-17 96 
(Fig. 2b, c). The independently derived cde-1 (tm1021) knockout strain also phenocopied viral 97 
stress sensor activation (Extended Data Fig. 3), high viral loads (Fig. 2d), and horizontal 98 
transmission of infection (Extended Data Fig. 3). RNA FISH revealed that viral infection is 99 
restricted to the intestine in cde-1 and in cde-1; drh-1 double mutants 4,9 (Extended Data Fig. 4a). 100 
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We validated that CDE-1 is present in the intestine using a GFP fusion 16 (Extended Data Fig. 4b). 101 
To disentangle between the functions of CDE-1 in different tissues, cde-1 was exclusively 102 
expressed from an intestine-specific vha-6p promoter (Extended Data Fig. 4c).  Animals with 103 
intestinal expression of cde-1 became resistant to viral infection (Extended Data Fig. 4d), but kept 104 
a defect in meiotic chromosome segregation (Extended Data Fig. 4e), probably caused by CDE-1 105 
depletion in the germline 15. CDE-1 contains a conserved triad of acid aspartic residues (DDD) in 106 
its nucleotidyltransferase domain. Mutation of the corresponding DDD triad to DAD (D1011A) in 107 
human TUT4 resulted in loss of catalytic activity 18. A cde-1 DAD mutant strain (Fig. 2a,c) showed 108 
similar viral susceptibility as the cde-1 null mutants (Fig. 2d). In summary, we identify CDE-1-109 
mediated 3ʹ terminal uridylation as an antiviral activity in the intestine of C. elegans. 110 
 111 
CDE-1 exert its antiviral function independently of antiviral RNAi 112 
In eukaryotes, addition of 3ʹ uridyl-tails (U-tails) by TUTs is a degradation signal that can engage: 113 
(i) the XRN-family of exoribonucleases for 5ʹ to 3ʹ RNA decay; (ii) the 3ʹ to 5ʹ exoribonuclease 114 
DIS3L2; (iii) the 3ʹ to 5ʹ exosome complex 19-22. We sought to identify the RNA(s) targeted by 115 
CDE-1 in its antiviral role. CDE-1 is implicated in endogenous RNAi pathways that are restricted 116 
to the germline 15. Small RNA sequencing on whole animals revealed that siRNAs are targeted by 117 
CDE-1 for 3ʹ uridylation, miRNAs are occasionally targeted, and piRNAs are not targeted 15 118 
(Extended Data Fig. 5a). The role of CDE-1 in small RNA function remains unclear as depletion 119 
of CDE-1 leads to only subtle changes in siRNA and miRNA steady state levels (Extended Data 120 
Fig. 5b, c). To understand if CDE-1 functions through modification of siRNAs in antiviral 121 
immunity, we tested cde-1 mutants directly for defects in antiviral RNAi. During an antiviral RNAi 122 
response in C. elegans, the ViRC complex recognizes the dsRNA of the replicating viral genome 123 
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and dices it into sense and antisense ~23-nt long primary viRNAs, which are loaded into the RDE-124 
1 Argonaute protein 5 (Fig. 3a). The RNAi response is further amplified by RNA-dependent RNA 125 
polymerase (RdRP, RRF-1) generated 22-nt long antisense secondary viRNAs, with a 5ʹ 126 
triphosphate guanine (22G-RNAs), which are incorporated into secondary Argonaute proteins to 127 
silence viral amplification 5 (Fig. 3a). Thus, in an animal with functional antiviral RNAi, a high 128 
viral load should correlate with a high level of viRNAs. We measured primary and secondary 129 
viRNAs in different genetic backgrounds (Fig. 3b,c). All the mutants tested (drh-1, rde-1, cde-1) 130 
accumulate high levels of the virus as compared to wild type. In drh-1 mutants, primary and 131 
secondary viRNAs are depleted when compared to wild type, despite the increase in viral load. In 132 
rde-1 mutants, primary viRNAs are abundant but secondary viRNAs are depleted, as in drh-1. In 133 
contrast, cde-1 mutants accumulate both primary and secondary viRNAs to a level that correlates 134 
with the high viral load. To determine if viRNAs can silence viral amplification in cde-1 mutants, 135 
we carried out epistasis analysis using null mutants of drh-1, rde-1 and cde-1 (Fig. 3d,e). Both 136 
cde-1;drh-1 and cde-1;rde-1 double mutants showed an increase in viral load as compared to drh-137 
1 or rde-1 on its own. We conclude that CDE-1 does not exert its immune function through the 138 
antiviral RNAi pathway. 139 
 140 
CDE-1 defines a novel antiviral immunity pathway 141 
In mammals, uridylation is coupled to poly(A) tail length where TUT4 and TUT7 preferentially 142 
uridylate mRNAs with short poly(A) tails (<25 nt) to facilitate their degradation 23,24 (Fig. 4a). We 143 
thus assessed the impact of CDE-1 on endogenous mRNA poly(A) tail lengths and terminal 144 
nucleotide addition in infected wild-type or cde-1 mutant animals using TAIL-seq 23,25. The C. 145 
elegans transcriptome revealed a bimodal distribution of poly(A) tail lengths, with a major peak 146 
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of poly(A) tails of ~40 nt, and a second peak of poly(A) tails of ~10 nt (Fig. 4b; using our method 147 
we could not assess transcripts with poly(A) tails > 79 nt). In cde-1 mutants, there is a shift of the 148 
major ~40 nt peak to ~36 nt and an increase in transcripts with shorter poly(A) (Fig. 4b). We infer 149 
that CDE-1 promotes the degradation of transcripts with short poly(A) tails in C. elegans too. 150 
However, CDE-1 had no global effect on the poly(A) tail distribution of OrV-induced stress 151 
response genes (Extended Data Fig. 6a). Also, the OrV-induced stress response was stronger in 152 
cde-1 mutants than in wild-type upon infection (Extended Data Fig. 6b), reflecting the difference 153 
in viral load between these two strains. This indicates that CDE-1 is not required for the OrV-154 
induced stress response. Although we cannot formally rule out that CDE-1 may regulate an 155 
endogenous target(s), the evidence indicates this is not CDE-1’s principal function in antiviral 156 
immunity. 157 
 158 
Instead, we postulated that the viral RNA genome itself may be uridylated by CDE-1. U-tails can 159 
only be observed on a small percentage of cellular RNAs as uridylated RNAs are prone to be 160 
degraded 24. To detect uridylated Orsay RNA degradation intermediates, we carried out 3ʹ rapid 161 
amplification of cDNA ends (RACE) followed by high-throughput sequencing of the OrV RNAs 162 
extracted from C. elegans two days postinfection (RACE-seq; Extended Data Fig. 7a). Mono(U) 163 
tails constituted the most abundant fraction of non-templated nucleotides detected at the 3ʹ end of 164 
both OrV RNA1 and OrV RNA2 (Fig. 4c-e). For both RNA1 and 2, U-tailing was lost in two 165 
independent cde-1 mutant alleles. In contrast, drh-1 and rde-1 mutants showed similar levels of 166 
viral RNA U-tails to wild-type, indicating that U-tailing is independent of viral load and that CDE-167 
1 is not in limited quantities (Extended Data Fig. 7b,c). OrV RNA1 and RNA2 have a terminal 168 
uridylyl residue in their genome such that the addition of an extra non-templated uridine by CDE-169 
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1 forms a UU termination (Fig. 4d), which is a signal for uridylation-dependent RNA decay 19,21. 170 
The two XRN paralogs in C. elegans (XRN-1 and XRN-2) and the exosome components (e.g. 171 
DIS-3, EXOS-2) are essential 26,27, and these RNA degradation pathways normally act redundantly 172 
on uridylated RNAs 24. We therefore subjected C. elegans to a short (24 hours) RNAi treatment to 173 
effect a partial knockdown of cde-1, the exonuclease disl-2 (the C. elegans DIS3L2 homologue), 174 
the exosome components exos-2 and dis-3, and the exonuclease xrn-2. Treated animals, which 175 
appeared superficially wild type, were infected with OrV for 24 hours. The frequency of U-tails in 176 
OrV RNA2 was measured by RACE-seq (Fig. 4f). ~4% of OrV RNA2 were uridylated in animals 177 
exposed to the empty vector control RNAi, compared to ~1% in cde-1 knockdown. RNAi 178 
treatments against disl-2 did not affect the U-tail frequency. We measured a 1.4 to 1.7 fold increase 179 
in U-tail frequency upon RNAi treatment against exos-2, dis-3 and xrn-2, suggesting that these 180 
factors each contribute to the degradation of uridylated viral RNAs, in accordance with a study 181 
that shows that DIS3 and the exosome can degrade viral RNAs in Drosophila and human cells 28. 182 
We conclude that C. elegans uses uridylation of the OrV as an innate immune defense. This 183 
mechanism acts in parallel to antiviral RNAi to combat viral infection (Fig. 5). 184 
 185 
Terminal uridylyltransferases target viral RNAs in mammalian cells 186 
The U-tail modification is conserved in eukaryotes and could impact a broad range of viruses in a 187 
variety of hosts 29. We tested if U-tailing affects the replication of Influenza A virus (IAV), which 188 
can infect human and murine cells. The IAV genome consists of eight antisense RNA segments 189 
(viral RNAs, vRNAs) from which the viral RdRP produces: (i) the sense complementary RNAs 190 
(cRNAs), which serve as templates to produce more vRNAs; and (ii) the mRNAs that are 3ʹ 191 
polyadenylated and exported to the cytosol for translation into viral proteins 30 (Fig. 6a). We 192 
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examined the 3ʹ end of a set of IAV RNAs, at 8 hours post-infection (hpi), in A549 human lung 193 
cells by RACE-seq. We could not detect U-tails at the ends of vRNAs or cRNAs. In contrast, viral 194 
mRNAs were highly uridylated at their 3ʹ end, with ~77% of the IAV Nucleoprotein (NP) mRNA 195 
containing a U-tail, and a di(U)-tail being the most common type of 3ʹ end (~32%) (Fig. 6b-e). 196 
The IAV NP mRNA is also uridylated (~40-50%) at 8 hpi in mouse embryonic fibroblasts (MEFs), 197 
but uridylation was lost in MEFs deficient in both Tut4 and Tut7 23 (Fig. 6f). Thus TUT4/7 can 198 
uridylate the 3ʹ end of viral RNAs in mammalian cells. The RACE-seq can only detect IAV 199 
mRNAs with poly(A) tails of <70 nt; it is possible that some IAV mRNAs with very long poly(A) 200 
tails are less prone to be uridylated. To test the impact of TUT4/7 on IAV, we measured the 201 
quantity of NP mRNA by qRT-PCR in infected MEFs (Extended Data Fig. 8a). The IAV NP 202 
mRNA accumulated more rapidly and to a higher level at the peak in MEFs Tut4/7 KO cells (peak 203 
at 8 hpi) compared to WT cells (peak at 16 hpi) before decreasing later in infection (24 hpi). 204 
Consistent with the difference in mRNA levels, the NP mRNA-encoded viral nucleoprotein (NP) 205 
accumulated more rapidly in MEFs Tut4/7 KO cells compared to WT during the first eight hours 206 
of infection (Extended Data Fig. 8b). Accordingly, more infected cells overall were observed in 207 
MEFs Tut4/7 KO compared to WT (Fig. 6g). In conclusion, TUT4/7 could act as an early barrier 208 
against IAV infection in mammalian cells. Although we cannot rule out that TUT4/7 may impact 209 
other steps of the IAV viral cycle, such as entry, our data strongly supports a model where TUT4/7 210 
act by reducing the expression levels of IAV mRNAs during the early stages of IAV infection in 211 
MEFs, leading to a decrease in viral protein levels and rates of infection. Future studies will need 212 
to address the antiviral function of TUT4/7 in a variety of relevant host-virus models. 213 
 214 
 215 
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DISCUSSION 216 
Previously, we have shown that the antiviral RNAi pathway and DRH-1 are central to the innate 217 
immune response of C. elegans 5. Here, we demonstrate that the terminal uridylyltransferases also 218 
play a critical role in antiviral immunity, uridylating viral RNAs (with 1-2 Us) to mark them for 219 
degradation. It is unclear how terminal uridylyltransferase recognize viral RNAs as bona fide 220 
targets. Receptors of the RIG-I family commonly recognize pathogen-associated patterns at the 5ʹ 221 
termini of viral RNAs. In contrast, terminal uridylyltransferases interact with the 3ʹ termini of 222 
cytosolic RNAs with no poly(A)-tail or a short poly(A)-tail. As many RNA viruses, like OrV, lack 223 
a poly(A) tail at the 3ʹ termini of their RNA genomes, this may be a pathogen-associated pattern-224 
recognition feature. We speculate that the IAV mRNAs and a fraction of the OrV RNAs are 225 
vulnerable to TUTs when exposed in the cytosol for translation. In conclusion, we find that 226 
terminal uridylyltransferases are potent antiviral factors during the early stages of RNA virus 227 
infections in C. elegans and in mammalian cells. This finding supports a scenario where eukaryotic 228 
mRNA decay pathways originally evolved as intrinsic cellular defenses against pathogens 31,32. 229 
Vertebrates also benefit from the interferon response and adaptive immune system, serving as 230 
potent lines of defense against pathogenic viruses; future studies will thus need to address the 231 
relative importance of antiviral uridylation in whole organisms. Terminal uridylyltransferases are 232 
widely conserved in eukaryotes and could potentially target a wide range of RNA viruses 29. 233 
Perhaps as a response to this threat, some viruses evolved to protect their RNA termini, such as 234 
single-stranded RNA viruses of the Flaviviridae family, which have highly structured 3ʹ ends 235 
resistant to degradation by cellular exonucleases 33. Our study illustrates that the 3ʹ termini of viral 236 
RNAs are key in the evolutionary arms race between viruses and their hosts. 237 
 238 
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METHODS 239 
Genetics 240 
Animals were grown on agar plates, at 20°C, and fed with E. coli strain HB101 (obtained from the 241 
Caenorhabditis Genetics Center, University of Minnesota, USA). Standard C. elegans procedures 242 
were used for maintenance and genetic crosses 34. The wild-type strain refers to Bristol N2 unless 243 
stated otherwise. All strains used in this study are listed in the Supplementary Table 2. 244 
 245 
PCR primers 246 
All PCR primers used in this study are listed in the Supplementary Table 3. 247 
 248 
Viral filtrate preparation 249 
Viral filtrate was prepared as in 8. Briefly, JU1580 animals were first stably infected by the Orsay 250 
virus (OrV) in solid culture and then transferred in a liquid culture containing OP50 bacteria for 251 
seven days. The liquid culture with infected JU1580 was then centrifuged at 16,000 g for 30 min 252 
and the supernatant was filtered (0.22 µm filter) to produce the viral filtrate (stored at -80°C). 253 
 254 
Transgenesis of C. elegans with the lys-3p::GFP viral stress sensor 255 
The 452 bp region upstream of the lys-3 start codon and the first 57 bp of the coding region of lys-256 
3 were used as a promoter and cloned into an entry clone using Multi-Site Gateway cloning 257 
(Invitrogen) according to manufacturer's instructions. The lys-3 donor plasmid was validated by 258 
sequencing. Gateway technology was then used to clone the lys-3 fragment in frame with a GFP 259 
cDNA. The 3ʹ UTR of the tbb-2 (tubulin, beta) gene was used. The lys-3p::GFP:tbb-2-3ʹUTR 260 
plasmid was amplified and purified according to Invitrogen's instruction. The C. elegans 261 
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microinjection mix was: 5 ng/µl plasmid lys-3p::GFP:tbb-2-3ʹUTR; 5 ng/µl co-injection marker 262 
(myo-2::mcherry::unc-54-3ʹUTR, pharynx expression) and 85 ng/µl 1 kb Invitrogen ladder in 1× 263 
injection buffer (20 mM potassium phosphate, 3 mM potassium citrate, pH 7.5). This mix was 264 
microinjected into the gonads of rde-1 (ne219) mutants to generate a multicopy extrachromosomal 265 
array (allele mjEx547). X-ray integration of the transgene into the C. elegans genome was 266 
performed as described previously 35. Animals carrying an integrated transgene (allele mjIs228) 267 
were outcrossed three times to generate SX2635 (lacking ne219), referred to as wild-type viral 268 
stress sensor strain in this study. 269 
 270 
Confocal images of the biostress reporter 271 
A 2% agar pad was used on top of a glass slide and a drop of 10 µM tetramisol in M9 medium was 272 
placed on this agar pad. Animals were picked into the tetramisol solution. Imaging was performed 273 
with an Olympus Upright FV1000 microscope at 10× or 20× magnification, as specified, using the 274 
FluoView image software (Olympus). Identical microscope settings were used for all images 275 
within a figure. 276 
 277 
Forward genetic screen for Ovid screen isolates 278 
Approximately 4,000 viral stress sensor transgenic animals were mutagenized using ethyl 279 
methanesulfonate (EMS) as described in 34 and 36. Approximately 50,000 F2 animals were infected 280 
for 3-4 days and ~2,000 animals showing intestinal GFP were picked individually for re-testing. 281 
16 F2 families showed transmission of the viral stress sensor activation. Bleach treatment 282 
confirmed that removing OrV lead to a loss of intestinal GFP signal. 283 
 284 
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C. elegans infection by the Orsay virus 285 
Animals were either infected for four days as asynchronous populations or for two days as 286 
synchronous populations. Infections of asynchronous populations were performed as in 5. Briefly, 287 
two L4 hermaphrodites were distributed in each 50 mm plates and, on the next day, 20 µl of viral 288 
filtrate was spread on the plates. Animals were harvested (for viral load measurement) or observed 289 
under a Leica M165 FC fluorescent microscope (for scoring of the viral stress sensor) four days 290 
post-infection (4 dpi). This method was typically used for the characterization of the Ovid screen 291 
isolates. For the infection of synchronous populations, 200 animals at the larval stage L1 were 292 
deposited on each 50 mm plate. On the next day, L2 animals were infected with 20 µl of viral 293 
filtrate homogeneously spread on the plate. Plates were kept up-side-up for 24 hrs. Animals were 294 
harvested for viral load measurement at 2 dpi. This method was used to measure the viral load in 295 
cde-1 mutants, as indicated in the figure legends. 296 
 297 
RNA level measurement by qRT-PCR 298 
Harvested animals were washed three times by pelleting-resuspension in M9 solution. Lysis and 299 
qRT-PCR was then performed from 5 µl of animal pellet using the Power SYBR Green Cells-to-300 
Ct kit (Ambion, Austin, TX) as described in 5. The primers M1835 and M1836 13, and M4410 and 301 
M4411 4, were used to measure RNA levels of gapdh and OrV gRNA1, respectively. 302 
 303 
RNAi-mediated knockdown of unc-22 304 
All the bacterial feeding clones used in this study were a kind gift from the laboratory of Julie 305 
Ahringer. Bacteria were grown in LB-Ampicillin (50 µg/ml) for 6 hrs, then seeded onto 50 mm 306 
NGM agar plates containing 1 mM IPTG and 25 µg/ml Carbenicillin at a volume of 300 µl bacterial 307 
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culture per plate and left to dry at room temperature, protected from the light, for 48 hrs. Two L4 308 
animals were picked onto each RNAi plates and the young adult progeny were scored for the 309 
phenotype of interest after five days. 310 
 311 
Transgenesis of C. elegans with the CDE-1::GFP fosmid and imaging 312 
The modified fosmid WRM064A_D06 where the GFP sequence is added at the N-terminal end of 313 
cde-1 was provided by the TransgeneOme Project (Max Planck Institute of Molecular Cell Biology 314 
and Genetics, TransgeneOme Unit, Pfotenhauerstr. 108, 01307 Dresden, Germany; construct 315 
09318202437763223 H08) 37. The construct was injected into the gonad of N2 animals to produce 316 
an extrachromosomal array (as described for the biostress reporter), using a myo-317 
3p::mCherry::unc-54-3′UTR construct as a co-injection reporter. Transgenic animals (strain 318 
SX3123; allele mjEx594) were imaged with an Olympus Upright FV1000 microscope at 10x 319 
magnification. 320 
 321 
Fluorescence in situ hybridization of the Orsay virus RNA2 322 
Animals were harvested in 15 ml of nanopure water and washed three times by pelleting-323 
resuspension in nanopure water. Animals were then transferred to 1.5 ml tubes with a glass pipette. 324 
1 ml of fixative solution (4% formaldehyde in 1X PBS) was added and samples were incubating 325 
at room temperature, on a rotating wheel, for 45 min. Nematodes were then washed twice by 326 
pelleting-resuspension in 1 ml of 1x PBS. Pellet of animals was resuspended in 1 ml 70% ethanol 327 
and stored at 4°C. After removal of the ethanol, fixed nematodes were washed once in 1 ml of 328 
wash solution (10% formamide, 2X SSC). The animal pellet was resuspended in 100 µl of 329 
hybridization solution (10% dextran sulfate, 2X SSC, 10% formamide) with 1 µl 1:50 of the probe 330 
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v1580-RNA2-TexRed (ACCATGCGAGCATTCTGAACGTCA), a kind gift of Marie-Anne 331 
Félix, and incubated overnight at 30°C protected from the light. The next day, animals were 332 
washed three times in wash solution by pelleting-resuspension. Eventually, animals were 333 
resuspended in 1 ml wash solution with DAPI and incubated at 30°C for 30 min. Samples were 334 
centrifuged and supernatant was discarded. The animal pellet was resuspended in 1 ml of 2X SSC 335 
solution and stored at 4°C protected from light. Animals were then placed on a glass slide, in a 336 
drop of Vectashield anti-fade solution (Vector). Imaging was performed on an Olympus Upright 337 
FV1000 at 40x magnification, using the FluoView image software (Olympus). Same settings of 338 
fluorescence were used for all images compared. 339 
Transgenesis of C. elegans with the vha-6p::gfp plasmid and viral load measurement 340 
The 878 bp region upstream of the vha-6 start codon was used as a promoter and cloned into an 341 
entry clone using Multi-Site Gateway cloning (Invitrogen) according to manufacturer's 342 
instructions. The vha-6p donor plasmid was validated by sequencing. Gateway technology was 343 
then used to clone the vha-6p upstream of (i) the GFP cDNA, or (ii) the full length cde-1 gene 344 
(from ATG to STOP with endogenous introns). The 3ʹ UTR of the tbb-2 (tubulin, beta) gene was 345 
used. The vha-6p::GFP::tbb-2-3ʹUTR and vha-6p::cde-1::tbb-2-3ʹUTR plasmids were amplified 346 
and purified according to Invitrogen's instruction. The C. elegans microinjection mix was: 10 ng/µl 347 
plasmid vha-6p::GFP:tbb-2-3ʹUTR; 10 ng/µl plasmid vha-6p::cde-1::tbb-2-3ʹUTR; 5 ng/µl co-348 
injection marker (myo-2::mcherry::unc-54-3ʹUTR, pharynx expression) and 75 ng/µl 1 kb 349 
Invitrogen ladder in 1× injection buffer (20 mM potassium phosphate, 3 mM potassium citrate, pH 350 
7.5). This mix was microinjected into the gonads of cde-1 (tm1021) mutants to generate a 351 
multicopy extrachromosomal array (allele mjEx595). vha-6p driven GFP expression was only 352 
observed in the intestine. 100 animals carrying the extrachromosomal array were manually 353 
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selected for infection (from the L2 larval stage to young adult). 354 
 355 
Small RNA sequencing 356 
Small RNA libraries were prepared from infected animals as previously described in 5. We used 357 
pellets of animals, washed three times in M9 solution and resuspended in 1 ml of TriSure (Bioline) 358 
as a starting material. RNA extraction was performed according to manufacturer’s instructions. 359 
Some populations of siRNAs (including secondary viRNAs) contain a characteristic 5ʹ 360 
triphosphate group that has to be replaced by a 5ʹ monophosphate to allow the 5ʹ ligation step of 361 
the library preparation. For this purpose, 1 µg of RNA was put in solution with 1X 5ʹp 362 
polyphophatase buffer and 1 µl of 5ʹ polyphophatase (Epicentre) for a total volume of 20 µl, 363 
incubated for 30 min at 37°C and then submitted to phenol purification and resuspended in 5 µl of 364 
nuclease-free water. Treated RNA sample was entirely used as starting material for the TruSeq 365 
Small RNA kit (Illumina), following the manufacturer’s instructions, to make the so-called 5ʹ 366 
independent libraries. So-called 5ʹ dependent libraries were made by a similar procedure but 367 
without polyphophatase treatment, so that only 5ʹ monophosphate siRNAs (such as primary 368 
viRNAs) could be cloned. Libraries were submitted to the Gurdon Institute sequencing facility for 369 
Illumina HiSeq sequencing (SR36). Small RNA sequencing data was aligned to the Ensemble 370 
WBcel235 release of the C. elegans genome using STAR 38 (v2.5.1b). Briefly, the aligner will 371 
allow untemplated residues at the ends of an aligned sequence when run in local mode. 372 
Untemplated 3ʹ sequences were extracted and analysed using custom Python scripts. Details of the 373 
analyses for each small RNA subtype can be found in the source code. For miRNA differential 374 
expression, reads were counted against the miRBase miRNA annotations (miRBase21 hairpins, 375 
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WBcel235 genome) using featureCounts 39 (v1.5.0-p1). Differential expression analysis was 376 
performed on the counts using DESeq2 40 (v1.10.1). 377 
 378 
CRISPR/Cas9 for cde-1 catalytic dead mutant 379 
A CRISPR/Cas9-mediated mutation of cde-1 was generated as previously described 41. Guide 380 
RNA: UUUGCUGUCAAAUCCUUUGG. Homologous recombination template: 381 
TCAGCTATTGCTATTTGTTTGAGATTCGGAGATGGAGATGTTCCGCCTAAAGACTTG382 
ACAGCAAAAGAAGTTATTCAGAAAACTGAATCCGTTCTCAGAAAATGTCATTT. Only 383 
the D1069A missense mutation was introduced, as verified by sequencing. 384 
 385 
TAIL-seq 386 
The TAIL-seq was performed as previously described in 25. Tail-seq libraries were processed using 387 
Tailseeker 2 25. The 5ʹ and 3ʹ libraries were subsequently adapter trimmed using cutadapt 1.10 42 388 
with Illumina small RNA-seq adapters and filtered to a minimum length of 5bp. Trimmed 5ʹ reads 389 
were mapped with STAR 2.5.2a 38 against a combined meta-genome consisting of the C. elegans 390 
reference genome WBcel235 43 and the OrV genome 4. Mapping was performed in end-to-end 391 
mode allowing no mismatches and a gap opening and extension penalty of 10,000. Reads were 392 
assigned to genes with bedtools 2.26.0 44. Subsequently, 3ʹ reads without poly(A) tail or too many 393 
dark cycles were removed from the data. For the subsequent analysis, all C. elegans tags with 394 
poly(A) tail length equal to zero were discarded. Average poly(A) tail lengths and uridylation 395 
lengths for each sample were calculated as the arithmetic mean weighted by the support for each 396 
tag, reported by Tailseeker 2. The complete code is at https://github.com/klmr/poly-397 
u/tree/submitted. 398 
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 399 
mRNA libraries for deep sequencing 400 
mRNA libraries were prepared from three biological replicates per sample, using the NEBNext 401 
Ultra RNA non-directional Library kit with poly(A) selection (NEB), according to manufacturer’s 402 
instructions. Libraries were submitted to the Gurdon Institute sequencing facility for Illumina 403 
HiSeq sequencing (SR30). Differentially expressed genes were then called using EdgeR 45.  404 
 405 
3ʹ RACE-seq on the Orsay virus RNAs 406 
The 3ʹ RACE was performed on the same RNA input than that used for small RNA libraries, 407 
without polyphosphatase treatment. 200 ng of RNA were submitted to 3ʹ ligation using the TruSeq 408 
Small RNA kit (Illumina), following the manufacturer’s instructions. 3ʹ ligated RNA was used for 409 
reverse-transcription, still using the TruSeq Small RNA kit whilst bypassing the 5ʹ ligation step. 410 
The 3ʹ end of OrV RNA1 (or RNA2) genome was amplified by PCR (“PCR1”) from 2 µl of cDNA, 411 
using the primers M7454 and M7456 (or M7455 and M7456) and the Phusion High-Fidelity Taq 412 
Polymerase (NEB) with CG buffer, according to manufacturer's instructions. The thermocyler was 413 
programmed to 30 seconds at 98°C; 15 cycles of 5 seconds at 98 °C followed by 20 seconds at 414 
60°C and 10 seconds at 72°C. The 5ʹ adapter sequence from the TruSeq Small RNA kit was then 415 
introduced at the 5ʹ end of the amplicons by PCR (“PCR2”) using the primers M7456 and M7601 416 
for OrV RNA1 (or M7456 and M7602 for the OrV RNA2), using 2 µl of 1/10 diluted amplicon 417 
from PCR1 as a template and the same PCR conditions than that used in PCR1. The amplicons 418 
from PCR2 were purified using the DNA Clean & Concentrator-5 kit (Zymo Research) and 419 
resuspended in 10 µl of water. Resulting DNA was used as an input for the PCR amplification step 420 
of the TruSeq Small RNA kit, following the manufacturer’s instructions. Libraries were submitted 421 
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to the Gurdon Institute sequencing facility for Illumina HiSeq sequencing (PE100). The libraries 422 
were run on a 10% polyacrylamide gel for size selection (the amplicons could be visualized under 423 
UV light and the bands were cut at the same distance of migration for all samples). Paired-end 424 
reads obtained from the 3ʹ RACE experiment on the viral genome show overlap. The PEAR 425 
software 46 was used to merge the paired reads into a single read (v0.9.6, default parameters). 426 
Merged reads not starting with the targeted 3ʹ viral genome sequence fragment were discarded. 427 
The targeted viral genome sequence was removed from the remaining reads using custom python 428 
scripts (https://github.com/tdido/cde-1_analysis). The resulting sequences representing the 429 
untemplated tails were analyzed using custom python scripts. 430 
 431 
RNAi-mediated knockdown of exonucleases 432 
Synchronized animals were grown on normal HB101 food until the L2 larval stage and then 433 
transferred RNAi food. Animals were left on RNAi plate (24 hours prior to infection) and infected 434 
for 24 hours, from the old L3/young L4 larval stages to adult. RACEseq was performed as 435 
described above. 436 
 437 
Cell culture  438 
MEF cells were cultured with DMEM (GIBECO) supplemented with 12.5% FBS, 2mM L-439 
glutamine, non-essential amino acid,100 units/ml penicillin/streptomycin, 100 uM β-440 
mercaptoethanol (Sigma). Cells were splitted 1:4 and passaged every three days. A549 cells were 441 
cultured with DMEM (GIBECO) supplemented with 10% FBS, 2mM L-glutamine, non-essential 442 
amino acid,100 units/ml penicillin/streptomycin and 25mM HEPES. 443 
 444 
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Generation of Tut4/7 CTR and KO MEFs 445 
Tut4/7 CTR and KO MEFs were derived from E13.5 embryos from crosses 446 
of Tut4+/fl;Tut7+/fl;R26+/+ and Tut4+/fl;Tut7+/fl;R26ERT-cre/ERT-cre mice by standard procedures and 447 
immortalized at passage 2 by two consecutive infections with pBabeSV40LT. Cre-mediated 448 
deletion to obtain Tut4/7 null alleles was induced with 600 nM 4-hydroxytamoxifen for three days 449 
23. 450 
 451 
A549 and MEF cells infection by Influenza A virus and RACE-seq  452 
Influenza A virus (A/WSN/1933, H1N1) used in this study was titrated on MDCK cells. All the 453 
inoculation MOI of influenza A virus described here and below was calculated as an equivalent 454 
MOI on the originally titrated MDCK cells. 455 
A549 or MEF cells were trypsinized and seeded as 2X10^6 cells per T25 flask one day before 456 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 457 
pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 458 
with 1000 µl DMEM supplemented with 0.1% BSA (D0.1B). Cells were trypsinized and collected 459 
8 hours post infection. 750 µl TRIzol were added into each infected sample and were then freezed 460 
at -80 °C. RNA extraction was performed according to the standard TRIzol procedure. 461 
For the A549 RACE-seq, 2 µg of RNA were submitted to 3ʹ ligation using the TruSeq Small RNA 462 
kit (Illumina), following the manufacturer’s instructions. 3ʹ ligated RNA was used for reverse-463 
transcription, still using the TruSeq Small RNA kit (except that the Invitrogen Suprescript III was 464 
used instead of the Superscript II) whilst bypassing the 5ʹ ligation step. The RT final volume was 465 
12.5 µl. After the RT, water was added to the samples to reach 18.5 µl, final volume. The 3ʹ end 466 
of IAV RNAs were amplified by PCR (“PCR1”) from 2 µl of cDNA, using the left primers M8443, 467 
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M8444, M8451, M8452, M8453, M8454, M8455, M8456 (depending on the target, see the 468 
Supplementary Table 3) with the right primer M7456 and the NEB Q5 polymerase, according to 469 
manufacturer's instructions (25 µl reaction). The thermocyler was programmed to 30 seconds at 470 
98°C; 5 cycles of 5 seconds at 98 °C followed by 20 seconds at 60°C and 20 seconds at 72°C. 471 
Each PCR product was purified using the DNA Clean & Concentrator-5 kit (Zymo Research) and 472 
eluted in 11 µl of water. The 5ʹ adapter sequence from the TruSeq Small RNA kit was then 473 
introduced at the 5ʹ end of the amplicons by PCR (“PCR2”) using the left primers M8459, M8460, 474 
M8467, M8468, M8469, M8470, M8471, M8472 (depending on the target, see the Supplementary 475 
Table 3) with the right primer M7601, using 10 µl of purified PCR1 amplicon as a template and 476 
the same PCR conditions that used in PCR1. Again, the amplicons from PCR2 were purified using 477 
the Zymo columns and eluted in 11 µl of water. Resulting DNA was used as an input for the PCR 478 
amplification step of the TruSeq Small RNA kit, following the manufacturer’s instructions. 479 
Libraries were submitted to the Gurdon Institute sequencing facility for Illumina HiSeq sequencing 480 
(PE100). The libraries were run on a 10% polyacrylamide gel for size selection (the amplicons 481 
could be visualized under UV light and the bands were cut at the same distance of migration for 482 
all samples). Paired-end reads obtained from the 3ʹ RACE experiment on the viral genome show 483 
overlap. The PEAR software 46 was used to merge the paired reads into a single read (v0.9.6, 484 
default parameters). Merged reads not starting with the targeted 3ʹ viral RNA sequence fragment 485 
were discarded. The targeted viral genome sequence was removed from the remaining reads using 486 
custom python scripts (https://github.com/tdido/cde-1_analysis). The resulting sequences 487 
representing the untemplated tails were analyzed using custom python scripts. The MEFs RACE-488 
seq was identical to the A549 cells RACE-seq, except: (i) the starting material was 1 µg, (ii) the 489 
Invitrogen Superscript II was used for the RT, (iii) PCR1 and PCR2 had 10 cycles each. 490 
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 491 
MEFs infection by Influenza A virus and qRT-PCR 492 
MEF cells were trypsinized and seeded as 8X10^4 cells per well of 24-well plate one day before 493 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 494 
pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 495 
with 250 ul DMEM supplemented with 0.1% BSA (D0.1B). Cells were trypsinized and collected 496 
8, 16 and 24 hours post infection. 350 ul TRIzol were added into each infected sample. RNA was 497 
extracted using Direct-zol™ RNA MiniPrep (Zymo Research) purification according to the 498 
manufacture’s protocol and was finally eluted into 60 ul RNase/DNase free water.  The extracted 499 
RNA was subjected to strand specific qRT-PCR to quantify influenza virus replication as described 500 
in 47. 501 
 502 
MEFs infection by Influenza A virus and FACS assay 503 
MEF cells were trypsinized and seeded as 1X10^4 cells per well of 96-well plate one day before 504 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 505 
pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 506 
with 50 µl DMEM supplemented with 0.1% BSA (D0.1B).  Inoculum was removed after 1 hour 507 
of incubation at 37 °C. The infected cells were cultured with MEF cell culture medium with 508 
2.5% FBS. 8 hours post inoculation, culture media were removed and cells were trypsinized 509 
through incubation with 30 µl 0.05% trypsin for 3 minutes at 37 °C. Trypsinized cells were 510 
resuspended with 70ul of P2F (PBS with 2% FBS) and then fixed with 100 µl 4% PFA for 15 511 
minutes. Fixed cells were centrifuged at 300g for 5 minutes and then washed once with 100 µl 512 
P2F. Cells were then permeablized with buffer (0.1% Saponin, 10mM HEPES, 0.025% Sodium 513 
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Azide in 1XHBSS) for 15 minutes at room temperature and then spinned at 500g for 2 minutes 514 
to remove buffer. Primary anti-influenza A virus nucleoprotein antibodies were purchased from 515 
Millipore (MAB8258B | clone A3, biotin-conjugated). The primary antibodies were diluted 516 
1:2000 in permeable buffer and 50 µl diluted antibodies were added into each well of 96-well 517 
plate. Primary antibodies were incubated with infected cells at room temperature for 1 hour. The 518 
cells were then washed 3 times with permeable buffer. FITC conjugated goat anti-mouse 519 
secondary antibodies were purchased from Invitrogen and diluted at 1:1000 in permeable buffer. 520 
Secondary antibodies were incubated for 1 hour at room temperature and washed as described 521 
before. The stained cells were finally resuspended in 70 µl P2F. The cell suspension was run on a 522 
high throughput FACS machine (MACSQuant® analyzer 10 - Miltenyi Biotec). Uninfected cells 523 
were stained the same as infected cells and were used as negative staining cell populations. Any 524 
cells/events that had fluorescence intensity higher than all the negative staining cell population 525 
were gated as virus infection positive. Data were analyzed using flowjo software (version 10). 526 
 527 
ACCESSION CODES 528 
All raw sequencing data are deposited in GEO (small RNA sequencing: GSE80169; mRNA 529 
sequencing: GSE76901; TAILseq: GSE85893). All C. elegans strains created in this study will be 530 
freely available on a non-collaborative basis. Correspondence and requests for materials should be 531 
addressed to E.A.M. (eam29@cam.ac.uk). 532 
 533 
 534 
 535 
 536 
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TABLES 652 
Table 1 |  Ovid screen candidate genes 653 
Genotype High 
viral 
load? 
RNAi 
intact? 
High 
sdz-6 
level? 
Candidate 
gene 
Candidate 
variation 
Brief description 
WT No Yes Yes    
rde-1 Yes No Yes   RNAi factor 
drh-1 Yes Yes No   Viral RNA receptor 
ovid-1 Yes Yes No drh-1 Glu834Lys Viral RNA receptor 
ovid-2 Yes Yes Yes n.d.   
ovid-3 Yes No Yes mut-16 Gln861* RNAi factor 
ovid-4 Yes No Yes rde-4 Ala220Thr  RNAi factor 
ovid-5 Yes No Yes n.d.   
ovid-6 Yes Yes Yes T09B4.2 Pro330Leu Putative rho guanine 
nucleotide exchange 
factor 
ovid-7 Yes Yes Yes C41D11.6 Gly596Ser Putative RNA 
nuclease 
ovid-8 Yes Yes Yes n.d.   
ovid-9 Yes Yes Yes cde-1 Gln910*  Terminal 
uridylyltransferase 
ovid-10 Yes No Yes rrf-1 Gly45Glu RNAi factor 
ovid-11 Yes Yes Yes C54D10.14 Gly122Arg Uncharacterized, 
DRH-1-dependent 
induction 
ovid-12 Yes No Yes F27D4.6 Arg717* Uncharacterized 
ovid-13 n.s. Yes Yes n.d.   
ovid-14 n.s. Yes Yes n.d.   
ovid-15 n.s. Yes Yes n.d.   
ovid-16 Yes Yes Yes phi-32 
ssl-1 
Pro75Ser 
Gly1119Glu 
Ubiquitin gene 
SNF2-related 
n.s., not scored. n.d., not determined. 654 
 655 
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FIGURES 656 
Figure 1 | A forward genetic screen identifies novel antiviral immunity genes 657 
a, Diagram of the lys-3p::gfp viral stress sensor. 658 
b, Ovid screen workflow. Transgenic animals carrying the viral stress sensor were mutagenized 659 
using EMS and F2 progeny were assayed. OrV, Orsay virus. Ovid, Orsay virus immunodeficient. 660 
c, Top panel: viral load of strains as indicated, measured by qRT-PCR of OrV RNA1, 4 dpi. Error 661 
bars represent the standard error of the mean (SEM) of four biological replicates. One-tailed 662 
student’s t-test: ****p<0.0001, *** p<0.001, **p<0.01, *p<0.05. Bottom panel: locomotion 663 
defects scored (paralyzed or twitching) after unc-22 RNAi feeding. Error bars: SEM, three 664 
biological replicates. Two-tailed student’s t-test: ****p<0.0001, **p<0.01. 665 
d, Viral load compared to sdz-6 mRNA levels by qRT-PCR. Error bars: SEM of four biological 666 
replicates. Samples as in c. 667 
 668 
Figure 2 | The terminal uridylyltransferase CDE-1 restricts viral infection 669 
a, Diagram of cde-1 alleles. DAD, catalytic dead mutant. 670 
b, Neighbor joining tree of the terminal uridylyl transferases (TUTs) of C. elegans and humans 671 
and S. pombe CID1. 672 
c, Diagrams of C. elegans CDE-1 and human TUT4 and TUT7. Domains were predicted by 673 
Interpro. The central D of the conserved DDD catalytic triad is highlighted in red. 674 
d, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after infection. 675 
Five biological replicates per sample. One-tailed student’s t-test: **** p<0.0001, **p<0.01 676 
 677 
 678 
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Figure 3 | CDE-1 acts in parallel to antiviral RNAi 679 
a, Schematic of antiviral RNAi in C. elegans. Viral Recognition Complex (ViRC) includes DCR-680 
1; DRH-1; RDE-4. 681 
b, Comparison between the viral load and primary viRNA populations. Primary viRNAs (23-682 
nucleotide long, from 5ʹ monophosphate RNA sequencing). Only antisense RNAs were considered 683 
to exclude potential viral genome degradation products. Each data point represents one biological 684 
replicate (population of animals). 685 
c, Comparison between the viral load and secondary viRNA populations. Secondary viRNAs (22-686 
nucleotide long, starting with a G, from 5ʹ tri/monophosphate RNA sequencing). Samples as in b. 687 
d and e, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after 688 
infection. Five biological replicates per sample. One-tailed student’s t-test: *** p<0.001, 689 
**p<0.01, *p<0.05. Samples as in b. 690 
 691 
Figure 4 | CDE-1 directly targets the Orsay virus RNA genome for uridylation 692 
a, Schematic of TUT-mediated RNA degradation. 693 
b, Poly(A) tail length distribution measured by TAIL-seq after two days of OrV infection. Vertical 694 
grey line represents the mean of cde-1 and wild type peaks (38 nt). 695 
c, Schematic of Orsay virus replication 696 
d, Most frequent collapsed reads after RACE-seq on OrV RNA1 and RNA2 (2 dpi), respectively. 697 
Non-templated residues (absent from the reference genome) are indicated in red. 698 
e, Percentage reads with non-templated nucleotides detected at the 3ʹ end of OrV RNA1-2 in strains 699 
as indicated, two days post infection. Two biological replicates per genotype. 700 
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f, Percentage reads with a non-templated mono-uridyl residue at the 3ʹ end of OrV RNA2, upon 701 
RNAi-mediated gene knockdown as indicated, one day post infection. Two biological replicates 702 
per sample. 703 
 704 
Figure 5 | Antiviral RNAi and virus terminal uridylation are parallel immune defense 705 
pathways in C. elegans. Virion cartoon adapted from 12. 706 
  707 
Figure 6 | The terminal uridylyltransferases TUT4/7 attenuate Influenza A mRNAs in 708 
mammalian cells 709 
a, Schematic of Influenza A virus replication 710 
b-d, Most frequent collapsed reads after RACE-seq on IAV NP cRNA, NP vRNA and NP 711 
mRNA, respectively in A549 cells at 8 hpi. 712 
e, Percentage of reads with a non-templated U-tail (no U-tail; 1 U; 2 Us or ≥ 3 Us) in different 713 
RNAs as indicated measured by RACE-seq in A549 cells 8 hpi. 714 
f, Percentage of reads with a non-templated U-tail (as in e) in MEF cells of different genotypes 715 
as indicated (with two independently created cell lines per genotype). 716 
g-h, Percentage of infected cells measured by immunofluorescence against NP (FACS). Error: 717 
SEM, three biological replicates. MEFs Tut4/7 KO are full null independent lines. 718 
 719 
 720 
 721 
 722 
 723 
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EXTENDED DATA FIGURES 724 
Extended Data Figure 1 | The viral stress sensor (lys-3p::GFP) is constitutively active in some 725 
tissues  but is induced in the intestine upon severe viral infection. 726 
a, Comparison of viral load and the lys-3 and sdz-6 mRNA expression after two days of infection 727 
by qRT-PCR, strains as indicated. Each data point represents one biological replicate (population 728 
of animals on one agar plate). Samples as in Fig. 3d,e. 729 
b, Representative confocal sections (10× or 20× magnification, as specified) of the viral stress 730 
sensor in wild type and drh-1 mutants without infection. The viral stress sensor exhibited 731 
constitutive activity in uninfected individuals, which was restricted to specific tissues. GFP was 732 
observed at all developmental stages in the pharynx and the rectum of hermaphrodites. 733 
Additionally, hermaphrodites at the L4 larval stage would show a strong GFP signal around the 734 
vulva and gravid adults exhibited the GFP in the uterine lumen. In males, GFP was observed in 735 
the pharynx and the tail. GFP expression was comparable in wild type and drh-1 mutants and 736 
independent of viral infection. Thus, the gene lys-3 is constitutively active in tissues neighboring 737 
openings exposed to the environment, the most likely entry points of potential bacterial pathogens. 738 
c, Representative confocal sections (20× magnification) of young adults (strains as indicated) 739 
carrying the viral stress sensor. Animals were uninfected (mock) or infected with OrV for four 740 
days. The viral stress sensor was strongly induced in the intestine after infection of drh-1 mutants, 741 
which is in agreement with the tropism of OrV. Intestinal GFP was most often visible around the 742 
collar of the nematodes, in the anterior region of the intestine in young adults. Some infected 743 
individuals exhibited a strong GFP signal throughout their entire body (data not shown), 744 
suggesting that the induction of the viral stress sensor can spread from cell to cell, like an 745 
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inflammation process. The viral stress sensor offers an opportunity to easily monitor viral 746 
infections in living animals. 747 
 748 
Extended Data Figure 2 | A cde-1 deletion allele fails to complement the screen isolate ovid-749 
9. 750 
a, Workflow of cde-1/ovid-9 (mj414) × cde-1 (tm1021) F8 recombinant family generation. A 751 
similar strategy was used to construct the cde-1 (mj414) × drh-1 (ok3495) F8 recombinant families. 752 
All animals were homozygous for the viral stress sensor (mjIs228). 753 
b-c, Number of families that activated the viral stress sensor in more than 20% of individuals after 754 
four days of infection with OrV. Approximately 50 individuals were scored per agar plate. 755 
 756 
Extended Data Figure 3 | cde-1 mutants show horizontal transmission of Orsay virus 757 
infection 758 
Workflow and data monitoring the inter-individual transmission of OrV infection (in strains as 759 
indicated) using the viral stress sensor. 760 
 761 
Extended Data Figure 4 | Intestinal expression of cde-1 confers antiviral immunity 762 
a, Representative confocal sections (20× magnification) of OrV in vivo RNA FISH. 763 
b, Representative confocal section (10× magnification) of a C. elegans L4 larva expressing cde-764 
1::GFP. As two previous reports disagreed about the expression pattern of CDE-1 15,16, we used 765 
fosmid-recombineering to generate transgenic animals driving GFP expression from an 766 
endogenous genomic context. 767 
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c, Diagram of the cde-1 rescue transgene, using the intestine-specific promoter of the gene vha-6. 768 
This transgene was injected in cde-1 null mutants. 769 
d, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after infection. 770 
Error: SEM, five biological replicates. One-tailed student’s t-test: *** p<0.001, **p<0.01. 771 
e, Incidence of male in the progeny of hermaphrodites left to self-fertilize at 25°C, in strains as 772 
indicated. 773 
 774 
Extended Data Figure 5 | CDE-1 is not required for general miRNA homeostasis 775 
a, Non-templated nucleotides at the 3ʹ end of the different classes of endogenous and antiviral 776 
small RNAs as indicated. RNA was isolated from young adults after two days of infection with 777 
OrV. 778 
b, miRNA expression in cde-1 (tm1021) mutants as compared to wild type, samples as in a. 779 
c, piRNAs and endogenous 22G-RNAs abundance in cde-1 (tm1021) mutants as compared to wild 780 
type, normalised to library size. Each data point represents one biological replicate. Samples as in 781 
a. 782 
 783 
Extended Data Figure 6 | CDE-1-depleted animals show a high expression of stress response 784 
genes during Orsay virus infection 785 
a, Fold change in the length of poly(A) tails (measured by TAIL-seq) in cde-1 mutants compared 786 
to wild type. RNA was isolated from young adults after two days of OrV infection. 787 
b, Differential mRNA expression in cde-1 (tm1021) compared to wild type, two days of OrV 788 
infection (mRNA-seq). 789 
 790 
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Extended Data Figure 7 | The 3ʹ end of the Orsay virus genome contains CDE-1-dependent 791 
non-templated U-tails 792 
a, Simplified workflow of 3ʹ RACE-seq of OrV RNA1 and OrV RNA2. 793 
b-c, Comparison between the viral load and the fraction of non-templated mono(U) tails at the 3ʹ 794 
end of OrV RNA1 and OrV RNA2, respectively, in strains as indicated. Each data point represents 795 
one biological replicate. Samples as in Fig. 3d,e and Fig. 4e. 796 
 797 
Extended Data Figure 8 | The terminal uridylyltransferases TUT4/7 restrict Influenza A infection 798 
a, Protein level of the IAV NP measured by immunofluorescence (FACS). Error: SEM in three 799 
biological replicates. 800 
b, Level of expression of the IAV NP mRNA normalized to Gapdh in MEF cells of different 801 
genotypes as indicated. Error: SEM, three biological replicates. 802 
 803 
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SUPPLEMENTARY INFORMATION 812 
Supplementary Table 1 | Infection by the Orsay virus induces viral stress sensor in Ovid 813 
screen isolates. 814 
Strain Genotype % intestinal 
GFP mock 
% intestinal 
GFP OrV 
SX2635 WT 0 4 
SX2615 rde-1 0 42 
SX2790 drh-1 0 83 
SX2996 ovid-1 0 86 
SX2900 ovid-2 0 83 
SX2739 ovid-3 0 74 
SX2901 ovid-4 0 73 
SX2902 ovid-5 0 68 
SX2729 ovid-6 0 64 
SX2991 ovid-7 0   60 
SX2990 ovid-8 0 52 
SX3000 ovid-9 0 48 
SX2881 ovid-10 0 47 
SX2987 ovid-11 0 46 
SX2988 ovid-12 0 44 
SX2920 ovid-13 0 26 
SX2909 ovid-14 0 26 
SX2886 ovid-15 0 24 
SX2885 ovid-16 0 24 
 815 
The percentage of young adults exhibiting intestinal GFP was assessed after four days of 816 
infection by OrV or in non-infected animals (mock). 20 to 50 young adults were scored per plate, 817 
in three biological replicates (average values are shown here). The screen isolates ovid-818 
1,7,8,9,11,12 were backcrossed prior to GFP scoring (see Supplementary Table 2).  819 
 820 
 821 
 822 
 823 
 824 
 825 
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Supplementary Table 2 | C. elegans strains used in this study 826 
Genotype Strain Comment 
+ N2   
cde-1(mj453) III SX3186   
cde-1(tm1021) III RF1290   
cde-1(tm1021) III 
; drh-1(ok3495) 
IV 
SX2998   
cde-1(tm1021) III 
; mjEx595 
SX3265 Contains the intestine-specific 
cde-1 construct (vha-6p::cde-1) 
cde-1(tm1021) III 
; mjIs228 ? 
SX2999   
cde-1(tm1021) III 
; rde-1(ne219) V 
SX3004   
drh-1(ok3495) IV RB2519   
drh-1(ok3495) IV 
; mjIs228 ? 
SX2790   
F27D4.6(tm1098) 
I 
FX01098   
mjEx594 ? SX3123 Contains the cde-1::GFP fosmid 
(TransgeneOme construct) 
mjIs228 ? SX2635 Contains the biostress (lys-
3p::GFP) reporter 
ovid-1(mj417) SX2996 Backcrossed 2X to SX2635 
ovid-2(mj422) SX2900   
ovid-3(mj367) SX2739   
ovid-4(mj423) SX2901   
ovid-5(mj425) SX2902   
ovid-6(mj357) SX2729   
ovid-7(mj405) SX2991 Backcrossed 2X to SX2635 
ovid-8(mj369) SX2990 Backcrossed 2X to SX2635 
ovid-9(mj414) SX3000 Backcrossed 2X to SX2635 
ovid-10(mj403) SX2881   
ovid-11(mj354) SX2987 Backcrossed 3X to SX2635 
ovid-12(mj401) SX2988 Backcrossed 3X to SX2635 
ovid-13(mj432) SX2920   
ovid-14(mj431) SX2909   
ovid-15(mj408) SX2886   
ovid-16(mj407) SX2885   
rde-1(ne219) V WM27   
rde-1(ne219) V ; 
mjIs228 ? 
SX2615   
 827 
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Supplementary Table 3 | Primers used in this study 828 
Name Sequence Description 
M1835 TGGAGCCGACTATGTCGTTGAG RT-qPCR on gapdh - left 
M1836 GCAGATGGAGCAGAGATGATG
AC 
RT-qPCR on gapdh - right 
M4410 ACCTCACAACTGCCATCTACA RT-qPCR OrV RNA1 - left 
M4411 
  
GACGCTTCCAAGATTGGTATT RT-qPCR OrV RNA1 - right 
M4988 CAATGCATTTGAAGCTGGAC RT-qPCR on lys-3 - left 
M4989 CCATTAGCAAGCAAATTCTGG RT-qPCR on lys-3 - right 
M5041 ACAATCGGGCGTTCAATTC RT-qPCR on sdz-6 - left 
M5042 TCTGATAGCTGGCTGAGTGG RT-qPCR on sdz-6 - right 
M5472 GGGGACAACTTTGTATAGAAAA
GTTGCTTCGAAAGAAACCCAAT
CCTC 
cloning of lys-3p into gateway 
system - left 
M5473 GGGGACTGCTTTTTTGTACAAA
CTTGGAGGAGCTGGGAAAGAG
TAGCA 
cloning of lys-3p into gateway 
system - right 
M7316 CCGGAACCCATCACGAAATT PCR on cde-1 (mj414) for Sanger 
sequencing - left 
M7317 TCCATTTCAAAGTCTCCACAGA PCR on cde-1 (mj414) for Sanger 
sequencing - right 
M7454 ATGGCCAAACGTCTGAAACC OrV RNA1 3ʹ RACE - left 
M7455 CCAAAGTCGCTTGCTGTACA OrV RNA2 3ʹ RACE - left 
M7456 CCTTGGCACCCGAGAATTCCA OrV RNA1/2 3ʹ RACE - right 
M7601 GTTCAGAGTTCTACAGTCCGAC
GATCATGGCCAAACGTCTGAAA
CC 
OrV RNA1 3ʹ RACE (with TruSeq 
RA5 sequence) - left 
M7602 GTTCAGAGTTCTACAGTCCGAC
GATCCCAAAGTCGCTTGCTGTA
CA 
OrV RNA2 3ʹ RACE (with TruSeq 
RA5 sequence) - left 
M8443 GCTAATTGGGCAAGGAGACG IAV 3' RACE PB2 RNA 
complementary left   
M8444 GCTGGGTTCTTCTCCTGTCT IAV 3' RACE PB2 RNA genomic 
left   
M8451 CTCTCGGACGAAAAGGCAAC IAV 3' RACE NP RNA 
complementary left   
M8452 AAGTTCGGTGCACATTTGGA IAV 3' RACE NP RNA genomic 
left   
M8453 CGCAATCTGGACTAGTGGGA IAV 3' RACE NA RNA 
complementary left   
M8454 GCCTTGGTTGCATATTCCAGT IAV 3' RACE NA RNA genomic 
left   
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M8455 ACGGTTTGAAAAGAGGGCCT IAV 3' RACE MP RNA 
complementary left   
M8456 CGGTGTTCTTCCCTGCAAAG IAV 3' RACE MP RNA genomic 
left   
M8459 GTTCAGAGTTCTACAGTCCGAC
GATCgctaattgggcaaggagacg 
IAV 3' RACE PB2 RNA 
complementary left  (with TruSeq 
RA5 sequence)  
M8460 GTTCAGAGTTCTACAGTCCGAC
GATCgctgggttcttctcctgtct 
IAV 3' RACE PB2 RNA genomic 
left  (with TruSeq RA5 sequence)  
M8467 GTTCAGAGTTCTACAGTCCGAC
GATCctctcggacgaaaaggcaac 
IAV 3' RACE NP RNA 
complementary left  (with TruSeq 
RA5 sequence)  
M8468 GTTCAGAGTTCTACAGTCCGAC
GATCaagttcggtgcacatttgga 
IAV 3' RACE NP RNA genomic 
left  (with TruSeq RA5 sequence)  
M8469 GTTCAGAGTTCTACAGTCCGAC
GATCcgcaatctggactagtggga 
IAV 3' RACE NA RNA 
complementary left  (with TruSeq 
RA5 sequence)  
M8470 GTTCAGAGTTCTACAGTCCGAC
GATCgccttggttgcatattccagt 
IAV 3' RACE NA RNA genomic 
left  (with TruSeq RA5 sequence)  
M8471 GTTCAGAGTTCTACAGTCCGAC
GATCacggtttgaaaagagggcct 
IAV 3' RACE MP RNA 
complementary left  (with TruSeq 
RA5 sequence)  
M8472 GTTCAGAGTTCTACAGTCCGAC
GATCcggtgttcttccctgcaaag 
IAV 3' RACE MP RNA genomic 
left  (with TruSeq RA5 sequence)  
M8652 CCTTCCACAATGCCAAAGTT  gapdh gene specific RT primer 
M8581 CCAGATCGTTCGAGTCGTTTTTT
TTTTTTTTTTTCTTTAATTGTC 
IAV NP mRNA gene specific RT 
primer 
M8651 GGGTGTGAACCACGAGAAAT gapdh qRT-PCR primer left 
M8652 CCTTCCACAATGCCAAAGTT gapdh qRT-PCR primer right 
M8582 CCAGATCGTTCGAGTCGT IAV NP mRNA qRT-PCR primer 
left 
M8583 CGATCGTGCCCTCCTTTGCGAT
CGTGCCCTCCTTTG 
IAV NP mRNA qRT-PCR primer 
right 
HJ359 GATGGACAAACAGACAAACC Tut4-1GTF genotyping 
HJ360 GCAGTTGTGCTATATTGACTC Tut4-1GTR genotyping 
HJ365 TGATCAGAGCATGCATACTC Tut7-2GTF genotyping 
HJ366 AAACAAGAAGCAGAGGTCCA Tut7-2GTR genotyping 
 829 
 830 
 831 
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